Delhi-based Vyome Biosciences Pvt Ltd, a biopharma firm which makes pharmaceutical and consumer care products for skin conditions, announced clinical trial results for its first product which is a hair serum formulation.
According to Vyome, its VB001 product was tested on 168 patients that were affected by dandruff during a two-week study which was fully compliant with Good Clinical Practice (GCP) norms. The company claims that the patients reported a faster and greater reduction of dandruff compared with other anti-dandruff shampoos available in the market.
“VB001 appears to be an effective and safe formulation, and can be a very attractive treatment alternative for mild to moderate dandruff, offering quick and durable relief,” said Dr Abhijit Bapat, director - clinical research at Vyome.
According to the study, by using this product itching associated with dandruff was relieved faster with a 48 per cent reduction in itching observed by day nine compared with shampoo. After two weeks of treatment, 41 per cent of subjects reported a visible reduction in hair fall compared with 18.5 per cent subjects for shampoo.
“The patent-pending technology platform on which our hair serum product is based can find applications in other areas too, and Vyome is building an array of unique offerings for today’s discerning global consumer,” said N Venkat, co-founder and CEO of Vyome.
Venkat, who previously served as CEO of Emami and was president of companies like CavinKare, Shantha Biotechnics and Aurobindo Pharma, was appointed CEO of Vyome earlier this year.
Vyome was set up in August 2010 by three people—Dr Shiladitya Sengupta of Harvard Medical School, Dr Rajesh Gokhale of Institute of Genomics and Integrative Biology and Rajeev Mantri, an executive director of Navam Capital.
Navam Capital, which is an early-stage venture capital firm with a focus on internet, cleantech and life sciences among others, invested $1 million in Vyome in November 2010.
The company raised $3.35 million from Kalaari Capital, Navam Capital and Aarin Capital in 2012.
(Edited by Joby Puthuparampil Johnson) Leave Your Comment